Who are Relistor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lybalvi, Olinvyk, Symproic, Viberzi, Movantik, Nucynta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylnaltrexone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Relistor — Competitive Intelligence Brief

Relistor (METHYLNALTREXONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid Antagonist. Area: Pain.

marketed Opioid Antagonist Mu-type opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

Relistor (METHYLNALTREXONE) — Salix Pharms. Relistor works by blocking opioid receptors in the gut to alleviate constipation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relistor TARGET	METHYLNALTREXONE	Salix Pharms	marketed	Opioid Antagonist	Mu-type opioid receptor	2008-01-01
Lybalvi	SAMIDORPHAN	Alkermes Inc	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	2021-01-01
Olinvyk	OLICERIDINE	Trevena	marketed		Mu-type opioid receptor	2020-01-01
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01
Viberzi	ELUXADOLINE	AbbVie	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	2015-01-01
Movantik	NALOXEGOL	Averitas	marketed	Opioid Antagonist	Mu-type opioid receptor	2014-01-01
Nucynta	TAPENTADOL	Collegium Pharm Inc	marketed	Opioid Agonist	Mu-type opioid receptor	2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-08-23 — Lybalvi · 11351166 · US
2031-08-23 — Lybalvi · 11241425 · US
2031-08-23 — Lybalvi · 9126977 · US
2031-08-23 — Lybalvi · 10300054 · US
2031-08-23 — Lybalvi · 10716785 · US
2031-08-23 — Lybalvi · 11185541 · US
2031-08-23 — Lybalvi · 9517235 · US
2031-08-30 — Lybalvi · 9119848 · US
2032-02-13 — Lybalvi · 8778960 · US

Sponsor landscape (Opioid Antagonist class)

Adapt · 1 drug in this class
Averitas · 1 drug in this class
Bdsi · 1 drug in this class
Cubist Pharms · 1 drug in this class
Hikma · 1 drug in this class
Salix Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relistor — Competitive Intelligence Brief. https://druglandscape.com/ci/methylnaltrexone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab